Dermatology Reports最新文献

Mixed-pattern, essential syphilitic alopecia, uveitis, and papillitis in an immunocompetent patient with neurosyphilis. 混合型，原发性梅毒性脱发，葡萄膜炎和乳头炎在免疫功能正常的神经梅毒患者。

IF 2.3

Dermatology Reports Pub Date : 2025-07-22 DOI: 10.4081/dr.2025.10371

Sumeetha Swaminathan, Irina Lerman, Kathleen Mannava, Luca Zatreanu, Anna De Benedetto

引用次数: 0

Stevens-Johnson syndrome and toxic epidermal necrolysis in Saudi Arabia: a retrospective cross-sectional multicenter study. 史蒂文斯-约翰逊综合征和中毒性表皮坏死松解在沙特阿拉伯：一项回顾性横断面多中心研究。

IF 2.3

Dermatology Reports Pub Date : 2025-07-18 DOI: 10.4081/dr.2025.10275

Rayan Alkhodair, Yazeed Alowairdhi, Abdulrahman Alfawzan, Ali Alghamdi

{"title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Saudi Arabia: a retrospective cross-sectional multicenter study.","authors":"Rayan Alkhodair, Yazeed Alowairdhi, Abdulrahman Alfawzan, Ali Alghamdi","doi":"10.4081/dr.2025.10275","DOIUrl":"https://doi.org/10.4081/dr.2025.10275","url":null,"abstract":"Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are a spectrum of life-threatening mucocutaneous conditions. Despite having a lower incidence rate than other dermatological conditions, SJS/TEN has a high mortality rate. SJS/TEN is usually caused by newly administered medications, particularly antibacterials and anticonvulsants. Little research data on SJS/TEN in Saudi Arabia has been published. We aimed to bridge this gap by reviewing and investigating the etiologies, risk factors, interventions, and outcomes of patients diagnosed with SJS/TEN. This is a retrospective cross-sectional study conducted in National Guard Hospitals in Riyadh and Jeddah from January 2015 to July 2023. We reviewed all dermatology medical records diagnosed as SJS/TEN through clinical assessment and histopathology, confirmed by a dermatology consultant. Additionally, we excluded all non-Saudi patients and those referred to our center with outside reports without histopathology from the national guard hospitals. This study included 25 patients diagnosed with the SJS/TEN spectrum between January 2015 and July 2023. Nearly two-thirds of the patients were male (n=15, 60%), and the average age was 45.96 years. Almost half of the culprit agents were antibiotics. Six of the 25 patients died (24%). Four were males, all over 50 years old, and one female was 6 years old. All these patients had TEN, except for one with SJS. Septic shock was the cause of death in 4 patients. Given the evident high risk for patients contracting this condition, prospective research and analysis to understand the correlation between SJS/TEN, mortality, and treatment are warranted.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Diagnosis and epidemiologic overview of the spectrum of skin diseases in Central, Northeast, and Southern Ethiopia. 更正：埃塞俄比亚中部、东北部和南部皮肤病谱的诊断和流行病学概述。

IF 2.3

Dermatology Reports Pub Date : 2025-07-15 DOI: 10.4081/dr.2025.10530

The Publisher

引用次数: 0

Dermoscopy of kaposiform hemangioendothelioma: a case report. 卡样血管内皮瘤的皮肤镜检查1例。

IF 2.3

Dermatology Reports Pub Date : 2025-07-11 DOI: 10.4081/dr.2025.10363

Filomena Barbato, Maria Maddalena Nicoletti, Gaetano Licata, Eugenia Veronica Di Brizzi, Giuseppe Argenziano, Caterina Mariarosaria Giorgio

引用次数: 0

Primary cutaneous marginal zone lymphoma in a patient with multiple sclerosis under fingolimod therapy. 芬戈莫德治疗下多发性硬化症患者的原发性皮肤边缘区淋巴瘤。

IF 2.3

Dermatology Reports Pub Date : 2025-07-11 DOI: 10.4081/dr.2025.10237

Thilo Gambichler, Sera Selina Weyer-Fahlbusch, Markus Werner, Ulrika Schade, Lieselotte Bissels, Laura Susok

引用次数: 0

Efficacy of a topical polyphenol-based formulation in palmoplantar psoriasis: an observational study. 局部多酚基制剂治疗掌跖牛皮癣的疗效：一项观察性研究。

IF 2.3

Dermatology Reports Pub Date : 2025-07-08 DOI: 10.4081/dr.2025.10333

Simone Amato, Annunziata Dattola, Luigi Bennardo, Martina Tolone, Steven Paul Nisticò

{"title":"Efficacy of a topical polyphenol-based formulation in palmoplantar psoriasis: an observational study.","authors":"Simone Amato, Annunziata Dattola, Luigi Bennardo, Martina Tolone, Steven Paul Nisticò","doi":"10.4081/dr.2025.10333","DOIUrl":"https://doi.org/10.4081/dr.2025.10333","url":null,"abstract":"This single-arm observational study evaluated the efficacy and safety of a novel topical formulation containing a complex mixture of polyphenols (CMP) - a proprietary blend rich in oleocanthal and oleuropein aglycone (each >60%), along with hydroxytyrosol and other extra virgin olive oil (EVOO)-derived polyphenols - combined with triticum vulgare germ (TVG) oil, betaine, propanediol, and tocopheryl acetate in patients with mild palmoplantar psoriasis (PPP). Twenty participants (aged 20-55) applied the formulation twice daily for 8 days, with assessments conducted on days 0 (baseline), 5, and 8. Participants underwent a 60-day follow-up to assess the durability of benefits and potential late-onset adverse events. Clinical evaluations measured lesion extent, keratinization, inflammation, desquamation, and infiltration. A patient-reported questionnaire evaluated quality of life (QoL) and symptom burden. By day 8, the mean lesion extent had decreased by approximately 40%, inflammation had improved by about 50%, and desquamation had resolved fully in most cases. Patient-reported outcomes improve alongside clinical measures. At day 60, these improvements persisted in 85% of participants, and no adverse events emerged. The formulation's mechanism of action is hypothesized to involve the concerted antioxidant and anti-inflammatory activities of polyphenols (oleocanthal, oleuropein aglycone, and hydroxytyrosol) in synergy with TVG oil's supportive lipid matrix and other excipients. These findings suggest that EVOO-derived polyphenols formulated in TVG oil may serve as a valuable adjunct for managing PPP with good tolerability and sustained benefits.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Purpura following laser hair removal: a case report. 激光脱毛后紫癜1例报告。

IF 2.3

Dermatology Reports Pub Date : 2025-07-01 DOI: 10.4081/dr.2025.10295

Kalliopi Papadopoulou, Eleni Paschalidou, Despoina Kosta, Kalliopi Karamanolaki

引用次数: 0

The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review. 间充质干细胞治疗免疫介导的炎症性皮肤病的适用性：系统综述

IF 2.3

Dermatology Reports Pub Date : 2025-07-01 DOI: 10.4081/dr.2025.10112

Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi

{"title":"The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review.","authors":"Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi","doi":"10.4081/dr.2025.10112","DOIUrl":"https://doi.org/10.4081/dr.2025.10112","url":null,"abstract":"Mesenchymal stem cell (MSC) therapy holds promise for treating immune-mediated inflammatory skin diseases (IMIDs), particularly when conventional therapies are ineffective. Encouraged by their immunomodulatory capabilities and potential for disease modification, different clinical trials are investigating the efficacy and safety of MSCs in single IMIDs. This review aims to summarize the application of MSCs in IMIDs and explore their future clinical potential. We reviewed published studies from January 2016 to January 2024 on MSC treatment for IMIDs. We retrieved 18 clinical trials and 5 observational studies, encompassing 609 patients with psoriasis, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), alopecia areata (AA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). Improvements or complete remission were observed in up to 100% of cases for AA, SSc, and SLE, though complete remission rates were less frequent than improvement rates, ranging from 0% in AD to 50% in CSU. Adverse events (AEs) were generally mild; moderate-to-severe AEs were uncommon (4% in psoriasis, 2.6% in SLE, and 0.7% in SSc), and deaths from all causes were rare (6 patients with SSc and 15 patients with SLE). In conclusion, MSC therapy shows promising results in terms of at least partial clinical improvement for most IMIDs. Its effect is achievable after a single or a few administrations, with no significant toxicity. MSCs may fulfill an unmet need for patients unresponsive to conventional immunomodulating agents. However, most evidence still comes from clinical trials with heterogeneous designs and endpoints. Future larger controlled trials are needed to better elucidate their role in refractory IMIDs.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy. 阿达木单抗生物仿制药GP2017在斑块型银屑病24个月治疗期的疗效和安全性：来自意大利艾米利亚-罗马涅中心的真实经验

IF 2.3

Dermatology Reports Pub Date : 2025-07-01 DOI: 10.4081/dr.2025.10315

Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

{"title":"Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy.","authors":"Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti","doi":"10.4081/dr.2025.10315","DOIUrl":"https://doi.org/10.4081/dr.2025.10315","url":null,"abstract":"Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the effectiveness and safety of GP2017 in 171 patients from Emilia-Romagna, Italy. Patients were divided into two groups: 78 transitioned from the ADA originator, and 93 were biologic-naive. Changes in the Psoriasis Area and Severity Index (PASI) were analyzed. In the switch group, PASI scores remained stable, while the naive group achieved significant improvements (PASI 75: 52% at 3 months, 89% at 6 months). Adverse events leading to discontinuation were rare. The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report. 免疫检查点抑制剂治疗后BRAF突变晚期黑色素瘤伴眼部和皮肤毒性的持久完全缓解：1例报告

IF 2.3

Dermatology Reports Pub Date : 2025-06-17 DOI: 10.4081/dr.2025.10324

Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso

{"title":"Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report.","authors":"Carlotta Bertolina, Marinella Bertolotti, Claudia Leporati, Antonina Maria De Angelis, Sara Delfanti, Luigi Cerbone, Marco Ghiglione, Federica Grosso","doi":"10.4081/dr.2025.10324","DOIUrl":"https://doi.org/10.4081/dr.2025.10324","url":null,"abstract":"Here we report the case of a woman suffering from advanced melanoma who developed severe toxicities with BRAF and MEK inhibitors (BRAFis, MEKis), given as second-line therapy after failure of immunotherapy, who achieved a complete and durable response lasting for over 5 years. Significant progress has been achieved in the treatment of advanced melanoma with immune checkpoint inhibitors (ICIs) and targeted therapies using BRAFis and MEKis. While these treatments improve survival, they also pose risks of severe toxicities. Notably, when targeted therapy follows immunotherapy, immune-mediated toxicities may emerge months later due to tumor microenvironment modulation. Despite these risks, both approaches offer a durable response in eligible patients. Further understanding is needed to determine how prior immunotherapy may influence subsequent toxicity risks of target therapy. Understanding these factors could optimize treatment strategies and improve patient outcomes.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0